RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION
Aim. To assess effectiveness and safety of the hospital use of recombinant non-immunogenic staphylokinase in patients with acute ST-elevated myocardial infarction (STEMI).Material and methods. Recombinant non-immunogenic staphylokinase was administered during in-hospital stage of treatment of 93 pa...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2017-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1416 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227757525925888 |
|---|---|
| author | V. B. Kostogryz |
| author_facet | V. B. Kostogryz |
| author_sort | V. B. Kostogryz |
| collection | DOAJ |
| description | Aim. To assess effectiveness and safety of the hospital use of recombinant non-immunogenic staphylokinase in patients with acute ST-elevated myocardial infarction (STEMI).Material and methods. Recombinant non-immunogenic staphylokinase was administered during in-hospital stage of treatment of 93 patients with acute STEMI, followed by clinical and electrocardiographic assessment and angiographic verification of the degree of blood flow in the infarct-related coronary artery. Hemorrhagic complications, allergic reactions, and hospital mortality were also considered.Results. When monitoring electrocardiogram after 90 minutes from the first bolus of recombinant non-immunogenic staphylokinase, the decrease of ST segment by 50% to the isoline was found in 93.5% of patients. Intracranial and extra brain major and small bleedings were not observed, as well as allergic reactions. In the group of patients who underwent coronary angiography (n=15), antegrade blood flow TIMI 3 was visualized in 100% of cases. Hospital mortality was 6%.Conclusion. Modern thrombolytic drug of recombinant non-immunogenic staphylokinase demonstrated high effectiveness in recovery of blood flow in the infarct-related coronary artery, hemorrhagic safety, and easy to use in the bolus administration. |
| format | Article |
| id | doaj-art-cf928205378245fca3262d27f73f7e92 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2017-03-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-cf928205378245fca3262d27f73f7e922025-08-23T10:00:28ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532017-03-01131515410.20996/1819-6446-2017-13-1-51-541305RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTIONV. B. Kostogryz0Institute of Emergency and Reconstructive SurgeryAim. To assess effectiveness and safety of the hospital use of recombinant non-immunogenic staphylokinase in patients with acute ST-elevated myocardial infarction (STEMI).Material and methods. Recombinant non-immunogenic staphylokinase was administered during in-hospital stage of treatment of 93 patients with acute STEMI, followed by clinical and electrocardiographic assessment and angiographic verification of the degree of blood flow in the infarct-related coronary artery. Hemorrhagic complications, allergic reactions, and hospital mortality were also considered.Results. When monitoring electrocardiogram after 90 minutes from the first bolus of recombinant non-immunogenic staphylokinase, the decrease of ST segment by 50% to the isoline was found in 93.5% of patients. Intracranial and extra brain major and small bleedings were not observed, as well as allergic reactions. In the group of patients who underwent coronary angiography (n=15), antegrade blood flow TIMI 3 was visualized in 100% of cases. Hospital mortality was 6%.Conclusion. Modern thrombolytic drug of recombinant non-immunogenic staphylokinase demonstrated high effectiveness in recovery of blood flow in the infarct-related coronary artery, hemorrhagic safety, and easy to use in the bolus administration.https://www.rpcardio.online/jour/article/view/1416acute st-elevated myocardial infarctionthrombolytic therapyrecombinant non-immunogenic staphylokinase |
| spellingShingle | V. B. Kostogryz RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION Рациональная фармакотерапия в кардиологии acute st-elevated myocardial infarction thrombolytic therapy recombinant non-immunogenic staphylokinase |
| title | RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION |
| title_full | RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION |
| title_fullStr | RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION |
| title_full_unstemmed | RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION |
| title_short | RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION |
| title_sort | results of hospital use of recombinant non immunogenic staphylokinase in patients with st elevated myocardial infarction |
| topic | acute st-elevated myocardial infarction thrombolytic therapy recombinant non-immunogenic staphylokinase |
| url | https://www.rpcardio.online/jour/article/view/1416 |
| work_keys_str_mv | AT vbkostogryz resultsofhospitaluseofrecombinantnonimmunogenicstaphylokinaseinpatientswithstelevatedmyocardialinfarction |